Company Synaptogenix, Inc. 1185 Avenue of the Americas, 3rd Floor New York, NY 10036 (973) 242-0005 Investor Relations IR Contact T: 800-811-5591 [email protected]

Sep 23, 2020 · Meet the leadership team driving Synaptogenix's mission to advance innovative therapies for neurodegenerative diseases.

You are about to review presentations, reports and/or filings of Synaptogenix, Inc. , that contain time-sensitive information. The information contained therein is only accurate as of the date …

May 27, 2019 · Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT =Real-Time, RTB =Real-Time BATS BZX Price/Quote; not sourced from all ...

Nov 19, 2019 · For inquires related to investor relations, please use the contact information and form below.

Market Cap $57.7M Synaptogenix, Inc. | 1185 Avenue of the Americas, 3rd Floor New York, NY 10036 | www.synaptogen.com

Oct 5, 2020 · Mr. Silverman joined the Company as a Director and Chairman of the Board in August 2016. He is currently the Co–founder and Managing Member of Parkfield Funding LLC, …

This is an example page. It’s different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that …

is lower in apoE4 transgenic mice compared with apoE3 mice, indicating impaired synaptogen-esis (12, 13). ApoE4 is less efficient than apoE3 in transporting brain cholesterol (14) and is …

Apolipoprotein E (ApoE) is a critical signal for synaptogen-esis and synaptic maturation [101]. ApoE/cholesterol com-plex released from astrocytes is taken up through low-density …